Work

Target discovery for T cell therapy: next steps to advance Immunotherapies

Year: 2015

Type: article

Abstract: Investigators from academia and industry gathered on August 14, 2014, in Boston at the Inaugural ImVacS conference entitled “Target Discovery for T Cell Therapy: Next Step to Advance Immunotherapies”. Novel targets, discovery strategies and enabling technologies were presented and discussed.

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/s40425-015-0061-5

Authors: Adrian Bot, Joanna E Brewer, Zelig Eshhar, Stanley R Frankel, Emma Hickman, Achim A Jungbluth, Richard Morgan, Yoav Peretz, Laszlo Radvanyi, Carlos A Ramos, Paul F Robbins, Kai W Wucherpfennig

Institutions: Kite Pharma (United States), Adaptimmune (United Kingdom), Weizmann Institute of Science, Amgen (United States), Immunocore (United States), Memorial Sloan Kettering Cancer Center, Bluebird Bio (France), Bluebird Bio (United States), Caprion (Canada), Iovance Biotherapeutics (United States), Baylor College of Medicine, National Cancer Institute, National Cancer Institute, National Cancer Institute, Center for Cancer Research, Harvard University, Dana-Farber Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490

OpenAlex ID: W2126936769

FWCI: 0.13

Cites:

Cited by: 5

Related to: 10